Xu XY, Ding HG, Li WG, Jia JD, Wei L, Duan ZP, Liu YL, Ling-Hu EQ, Zhuang H, Hepatology CSO, Association CM. Chinese guidelines on management of hepatic encephalopathy in cirrhosis. World J Gastroenterol 2019; 25(36): 5403-5422 [PMID: 31576089 DOI: 10.3748/wjg.v25.i36.5403]
Corresponding Author of This Article
Xiao-Yuan Xu, MD, Professor, Department of Infectious Diseases, Peking University First Hospital, 8 Xishiku Street, Beijing 100034, China. xiaoyuanxu6@163.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Guidelines
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Sep 28, 2019; 25(36): 5403-5422 Published online Sep 28, 2019. doi: 10.3748/wjg.v25.i36.5403
Table 1 Evidence level and recommendation strength
Level
Detailed description
Evidence Level
A
High quality: Further research cannot change the reliability of these treatment assessment results.
B
Moderate quality: Further research may influence the reliability of these treatment assessment results, and may change the treatment assessment results.
C
Low or very low quality: Further research will very likely influence the reliability of these treatment assessment results, and will very likely change the treatment assessment results.
Recommendation strength
1
Strong recommendation: It is clearly shown that either the benefits of intervention clearly outweigh the disadvantages, or that the disadvantages outweigh the benefits.
2
Weak recommendation: The benefits and disadvantages are unclear, or, regardless of the quality of the evidence, the benefits and disadvantages are comparable.
Table 2 Classification of hepatic encephalopathy recommended by the 11th World Congress of Gastroenterology in 1998
Type of hepatic encephalopathy
Definition
Subcategory
Subdivision
Type A
Hepatic encephalopathy associated with acute liver failure
None
None
Type B
Hepatic encephalopathy associated with portosystemic shunt and no liver cell injury-associated liver disease
None
None
Type C
Hepatic encephalopathy associated with cirrhosis with portal hypertension or portosystemic shunt
Table 4 Hepatic encephalopathy classification, symptoms, and signs
Revised HE grading criteria
Neuropsychiatric symptoms (that is, cognitive function)
Nervous system signs
No HE
Normal
Normal nervous system signs, normal neuropsychological test results
MHE
Potential HE, no noticeable personality or behavioral changes
Normal nervous system signs, but abnormal neuropsychological test results
HE grade 1
Trivial and mild clinical signs, such as mild cognitive impairment, decreased attention, sleep disorders (insomnia and sleep inversion), euphoria, or depression
Asterixis can be elicited and neuropsychological tests are abnormal
HE Grade 2
Marked personality or behavioral changes, lethargy or apathy, slight orientation abnormality (time and orientation), decreased mathematical ability, dyskinesia, or unclear speech
Asterixis is easily elicited, and neurophysiological testing is unnecessary
HE Grade 3
Marked dysfunction (time and spatial orientation), abnormal behavior, semi-coma to coma, but responsive
Asterixis usually cannot be elicited. There is ankle clonus, increased muscle tone, and hyperreflexia. Neurophysiological testing is unnecessary
HE Grade 4
Coma (no response to speech and external stimuli)
Increased muscle tone or positive signs of the central nervous system. Neurophysiological testing is unnecessary
Table 5 Notes on neuropsychological/physiological testing methods in clinical use
Testing methods
Testing purposes
Time
Remarks
Psychological tests
Psychometric hepatic encephalopathy score (PHES)
PHES is an important method for determining cognitive dysfunction and diagnosing MHE in cirrhosis patients
Includes five subtests, namely the number connection test A and B, digit symbol test, line tracing test, and serial dotting test
Pen and paper
Positives on at least two tests are required for clinical diagnosis
Number connection test A
Ability to concentrate, mental activity speed, can be used for rapid outpatient screening for MHE
30 to 120 s
Correction for age and education level improves accuracy
Number connection test B
Ability to concentrate, mental activity speed, distributed attention ability, can be used for rapid outpatient screening for MHE
1 to 3 min
Psychologist is required
More complicated than number connection test A
Digit symbol test
Ability to concentrate, mental activity speed, can be used for rapid outpatient screening for MHE
2 min
Psychologist is required
Stroop Smartphone app (Encephal App)
Attention, can be used for rapid outpatient screening for MHE
3 to 5 min
Reliable and easy to use
Repeatable battery for the assessment of neuropsychological status
Compliance and working memory, visual spatial ability, language, cognitive processing speed
25 min
Pen and paper
Psychologist is required
ISHEN recommends HE psychometric scores as substitute indicators
Inhibition control test
Attention, reaction inhibition, working memory
15 min
Computer processing
Patient cooperation is required, and patients must learn before testing
Neurophysiological testing
Flicker fusion frequency
Visual identification, can be used on outpatient basis for HE scores of 2 or lower, value of supplemental diagnosis is low
10 min
Patients must learn before testing
EEG
Generalized brain activity. Suitable for children
Variation
Psychologist and specialized tools are required
Evoked potential
Tests the time difference between electrical stimulation and response
Variation
P300 hearing has been used for the diagnosis of MHE
Citation: Xu XY, Ding HG, Li WG, Jia JD, Wei L, Duan ZP, Liu YL, Ling-Hu EQ, Zhuang H, Hepatology CSO, Association CM. Chinese guidelines on management of hepatic encephalopathy in cirrhosis. World J Gastroenterol 2019; 25(36): 5403-5422